Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy)

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Maeng, M, Jensen, LO, Tilsted, H-H, Kaltoft, A, Kelbaek, H, Abildgaard, U, Villadsen, A, Aarøe, J, Thayssen, P, Krusell, LR, Christiansen, EH, Bøtker, HE, Kristensen, ES, Ravkilde, J, Madsen, MV, Sørensen, H, Rasmussen, KR, Thuesen, L & Lassen, JF 2011, 'Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy)' American Journal of Cardiology, vol. 108, no. 9, pp. 1232-7. https://doi.org/10.1016/j.amjcard.2011.06.037

APA

CBE

Maeng M, Jensen LO, Tilsted H-H, Kaltoft A, Kelbaek H, Abildgaard U, Villadsen A, Aarøe J, Thayssen P, Krusell LR, Christiansen EH, Bøtker HE, Kristensen ES, Ravkilde J, Madsen MV, Sørensen H, Rasmussen KR, Thuesen L, Lassen JF. 2011. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). American Journal of Cardiology. 108(9):1232-7. https://doi.org/10.1016/j.amjcard.2011.06.037

MLA

Vancouver

Author

Maeng, Michael ; Jensen, Lisette Okkels ; Tilsted, Hans-Henrik ; Kaltoft, Anne ; Kelbaek, Henning ; Abildgaard, Ulrik ; Villadsen, Anton ; Aarøe, Jens ; Thayssen, Per ; Krusell, Lars Romer ; Christiansen, Evald Høj ; Bøtker, Hans Erik ; Kristensen, Erik Steen ; Ravkilde, Jan ; Madsen, Morten Vesterager ; Sørensen, Henrik ; Rasmussen, Klaus R. ; Thuesen, Leif ; Lassen, Jens Flensted. / Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). In: American Journal of Cardiology. 2011 ; Vol. 108, No. 9. pp. 1232-7.

Bibtex

@article{2f33893cde414be3be0618da1accb39b,
title = "Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy)",
abstract = "Diabetes is associated with an increased risk of major adverse cardiac events after percutaneous coronary intervention. We compared clinical outcomes in patients with and without diabetes mellitus treated with the second-generation Endeavor zotarolimus-eluting stent (ZES) or the first-generation Cypher Select+ sirolimus-eluting stent (SES). We randomized 2,332 patients to treatment with ZESs (n = 1,162, n = 169 diabetics) or SESs (n = 1,170, n = 168 diabetics) and followed them for 18 months. Randomization was stratified by presence/absence of diabetes. The primary end point was major adverse cardiac events defined as a composite of cardiac death, myocardial infarction, or target vessel revascularization. Secondary end points included these individual end points plus all-cause mortality and target lesion revascularization. In diabetic patients, use of ZES compared to SES was associated with an increased risk of major adverse cardiac events (18.3{\%} vs 4.8{\%}, hazard ratio 4.05, 95{\%} confidence interval 1.86 to 8.82), myocardial infarction (4.7{\%} vs 0.6{\%}, hazard ratio 8.09, 95{\%} confidence interval 1.01 to 64.7), target vessel revascularization (14.2{\%} vs 3.0{\%}, hazard ratio 4.99, 95{\%} confidence interval 1.90 to 13.1), and target lesion revascularization (12.4{\%} vs 1.2{\%}, hazard ratio 11.0, 95{\%} confidence interval 2.59 to 47.1). In patients without diabetes differences in absolute risk decrease were smaller but similarly favored SES. In conclusion, implantation of ZESs compared to SESs is associated with a considerable increased risk of adverse events in patients with diabetes at 18-month follow-up.",
keywords = "Acute Coronary Syndrome, Aged, Angioplasty, Balloon, Coronary, Coronary Artery Disease, Diabetes Mellitus, Drug-Eluting Stents, Female, Humans, Male, Middle Aged, Myocardial Infarction, Retreatment, Risk Assessment, Sirolimus",
author = "Michael Maeng and Jensen, {Lisette Okkels} and Hans-Henrik Tilsted and Anne Kaltoft and Henning Kelbaek and Ulrik Abildgaard and Anton Villadsen and Jens Aar{\o}e and Per Thayssen and Krusell, {Lars Romer} and Christiansen, {Evald H{\o}j} and B{\o}tker, {Hans Erik} and Kristensen, {Erik Steen} and Jan Ravkilde and Madsen, {Morten Vesterager} and Henrik S{\o}rensen and Rasmussen, {Klaus R.} and Leif Thuesen and Lassen, {Jens Flensted}",
note = "Copyright {\circledC} 2011 Elsevier Inc. All rights reserved.",
year = "2011",
doi = "10.1016/j.amjcard.2011.06.037",
language = "English",
volume = "108",
pages = "1232--7",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Excerpta Medica, Inc",
number = "9",

}

RIS

TY - JOUR

T1 - Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy)

AU - Maeng, Michael

AU - Jensen, Lisette Okkels

AU - Tilsted, Hans-Henrik

AU - Kaltoft, Anne

AU - Kelbaek, Henning

AU - Abildgaard, Ulrik

AU - Villadsen, Anton

AU - Aarøe, Jens

AU - Thayssen, Per

AU - Krusell, Lars Romer

AU - Christiansen, Evald Høj

AU - Bøtker, Hans Erik

AU - Kristensen, Erik Steen

AU - Ravkilde, Jan

AU - Madsen, Morten Vesterager

AU - Sørensen, Henrik

AU - Rasmussen, Klaus R.

AU - Thuesen, Leif

AU - Lassen, Jens Flensted

N1 - Copyright © 2011 Elsevier Inc. All rights reserved.

PY - 2011

Y1 - 2011

N2 - Diabetes is associated with an increased risk of major adverse cardiac events after percutaneous coronary intervention. We compared clinical outcomes in patients with and without diabetes mellitus treated with the second-generation Endeavor zotarolimus-eluting stent (ZES) or the first-generation Cypher Select+ sirolimus-eluting stent (SES). We randomized 2,332 patients to treatment with ZESs (n = 1,162, n = 169 diabetics) or SESs (n = 1,170, n = 168 diabetics) and followed them for 18 months. Randomization was stratified by presence/absence of diabetes. The primary end point was major adverse cardiac events defined as a composite of cardiac death, myocardial infarction, or target vessel revascularization. Secondary end points included these individual end points plus all-cause mortality and target lesion revascularization. In diabetic patients, use of ZES compared to SES was associated with an increased risk of major adverse cardiac events (18.3% vs 4.8%, hazard ratio 4.05, 95% confidence interval 1.86 to 8.82), myocardial infarction (4.7% vs 0.6%, hazard ratio 8.09, 95% confidence interval 1.01 to 64.7), target vessel revascularization (14.2% vs 3.0%, hazard ratio 4.99, 95% confidence interval 1.90 to 13.1), and target lesion revascularization (12.4% vs 1.2%, hazard ratio 11.0, 95% confidence interval 2.59 to 47.1). In patients without diabetes differences in absolute risk decrease were smaller but similarly favored SES. In conclusion, implantation of ZESs compared to SESs is associated with a considerable increased risk of adverse events in patients with diabetes at 18-month follow-up.

AB - Diabetes is associated with an increased risk of major adverse cardiac events after percutaneous coronary intervention. We compared clinical outcomes in patients with and without diabetes mellitus treated with the second-generation Endeavor zotarolimus-eluting stent (ZES) or the first-generation Cypher Select+ sirolimus-eluting stent (SES). We randomized 2,332 patients to treatment with ZESs (n = 1,162, n = 169 diabetics) or SESs (n = 1,170, n = 168 diabetics) and followed them for 18 months. Randomization was stratified by presence/absence of diabetes. The primary end point was major adverse cardiac events defined as a composite of cardiac death, myocardial infarction, or target vessel revascularization. Secondary end points included these individual end points plus all-cause mortality and target lesion revascularization. In diabetic patients, use of ZES compared to SES was associated with an increased risk of major adverse cardiac events (18.3% vs 4.8%, hazard ratio 4.05, 95% confidence interval 1.86 to 8.82), myocardial infarction (4.7% vs 0.6%, hazard ratio 8.09, 95% confidence interval 1.01 to 64.7), target vessel revascularization (14.2% vs 3.0%, hazard ratio 4.99, 95% confidence interval 1.90 to 13.1), and target lesion revascularization (12.4% vs 1.2%, hazard ratio 11.0, 95% confidence interval 2.59 to 47.1). In patients without diabetes differences in absolute risk decrease were smaller but similarly favored SES. In conclusion, implantation of ZESs compared to SESs is associated with a considerable increased risk of adverse events in patients with diabetes at 18-month follow-up.

KW - Acute Coronary Syndrome

KW - Aged

KW - Angioplasty, Balloon, Coronary

KW - Coronary Artery Disease

KW - Diabetes Mellitus

KW - Drug-Eluting Stents

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Retreatment

KW - Risk Assessment

KW - Sirolimus

U2 - 10.1016/j.amjcard.2011.06.037

DO - 10.1016/j.amjcard.2011.06.037

M3 - Journal article

VL - 108

SP - 1232

EP - 1237

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -

ID: 33265420